Commentary: Younger patients are choosing tissue valves: Do the data match their fervor?

Forcillo, Jessica; Thourani, Vinod H.

doi:10.1016/j.jtcvs.2021.02.061

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biological valves, such as Carpentier‐Edwards PERIMOUNT valves (Edwards Lifesciences), have already begun to show the first positive signs in terms of low SVD rate. In patients aged <60 years, the bioprosthesis provided satisfactory clinical and hemodynamic outcomes for up to 15 years after surgery 11‐13 . A recent multicenter study from Piperata et al analyzed 2148 Carpentier‐Edwards Magna Ease valves and their 12‐year durability comparing outcomes of patients younger and older than 65 years of age 14 .…”

Section: Discussionmentioning

confidence: 99%

Clinical performance of a novel bioprosthetic surgical aortic valve in a German high‐volume center

Ahmad

Giammarino

Salamate

et al. 2022

Journal of Cardiac Surgery

View full text Add to dashboard Cite

Background and Aim Bioprosthetic surgical aortic valve replacement (SAVR) is increasingly adopted in younger patients. We aimed to analyze mid‐term follow‐up data after SAVR to assess the performance of the prosthesis. Methods Data were collected from a single‐center series of 154 patients, who underwent SAVR with a bioprosthetic heart valve with the RESILIA tissue at our Heart Centre in Siegburg. All procedural and midterm patient outcomes were documented. Results Patients had a mean age of 56.8 ± 9.9 years, 35.7% were female, and the mean logistic European system for cardiac operative risk evaluation (EuroSCORE) was 3.4 ± 3.6%. Diabetes (12.3%), atrial fibrillation (10.4%), and chronic obstructive pulmonary disease (COPD) (5.8%) were common comorbidities. The mean surgery duration was 163.8 ± 73.4 min, with the 23 mm (34.4%) and 25 mm (33.8%) heart valves being most frequently implanted. At 3‐year follow‐up, mean pressure gradient was 13.9 ± 5.9 mmHg, peak gradient was 23.6 ± 7.7 mmHg, and effective orifice area (EOA) was 1.9 ± 0.4 cm². No patient died during the operation, 3 (2.1%) patients within 30 days, and 4 (2.7%) thereafter with an overall mortality of n = 7. Of the surviving patients, 97.8% were in New York Heart Association (NYHA) class I/II and none had structural valve deterioration (SVD). Conclusion Results of our single‐center study indicate favorable procedural outcomes. The safety outcomes confirm preliminary earlier results of this novel bioprosthesis but include more patients and a longer midterm follow‐up.

show abstract

Section: Discussionmentioning

confidence: 99%